VVY Stock Price, News & Analysis

Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY) has announced it will release its Q1 2025 financial results and provide a corporate update on June 17, 2025. The company, which focuses on developing small molecule medicines for inflammatory and fibrotic disorders with an emphasis on kidney diseases, will host a public conference call and webcast at 3:00 pm CEST / 9:00 am EDT. Participants can access the live audio webcast through Vivoryon's website and join the conference call via phone by pre-registering through the provided link. Attendees are advised to join 15 minutes before the scheduled start time.

Vivoryon Therapeutics presented meta-analysis data for varoglutamstat, their lead drug candidate, at the 62nd ERA Congress in Vienna. The analysis combined results from two Phase 2 studies (VIVIAD and VIVA-MIND) conducted in the EU and US. The data showed statistically significant improvements in kidney function (eGFR) starting at week 24 and sustained through week 96. Notably, patients with diabetes demonstrated substantially larger benefits compared to non-diabetic participants. Varoglutamstat, a first-in-class glutaminyl cyclase inhibitor, showed both anti-inflammatory and anti-fibrotic effects. The company plans to advance the drug to a Phase 2b trial specifically focused on diabetic kidney disease patients with chronic kidney disease stage 3b/4, aiming to further investigate its effects on eGFR, proteinuria, and other kidney-specific markers.

Vivoryon Therapeutics N.V. (VVY) has strengthened its intellectual property portfolio with a new U.S. composition of matter patent for its lead drug varoglutamstat. The patent (US 12,312,335), granted after an accelerated examination, covers the active polymorph of varoglutamstat's salt form and provides exclusivity through 2044, with potential extension to 2049 under the Hatch-Waxman Act.

The company has also filed additional patents for medical use and dosing regimens in kidney disease, both as monotherapy and in combination with SGLT-2 inhibitors. Vivoryon's patent portfolio includes over 20 patent families and 400+ patent applications and issued patents covering major markets, with a focus on QPCT/L inhibitors for kidney diseases, inflammatory diseases, oncology, and fibrotic diseases.

Vivoryon Therapeutics N.V. (VVY), a clinical stage company specializing in small molecule medicines development, has announced its upcoming 2025 Annual General Meeting. The meeting is scheduled for Tuesday, June 24, 2025 at 1:00 PM CEST and will be held at NautaDutilh N.V.'s Amsterdam offices. The company, which focuses on modulating pathologically altered proteins, has made the complete agenda and related documents available on their corporate website.

Vivoryon Therapeutics has reported its full year 2024 financial results and announced a strategic shift towards inflammatory and fibrotic diseases, particularly focusing on kidney disease. The company's drug varoglutamstat showed significant improvement in kidney function in two independent Phase 2 studies.

Key highlights include:

• Statistically significant improvement in kidney function (eGFR) versus placebo in VIVIAD and VIVA-MIND studies
• Meta-analysis enables efficient design of Phase 2b study in diabetic kidney disease (DKD)
• Synergistic effect discovered when combining varoglutamstat with SGLT2 inhibitor
• New U.S. patent allowance for varoglutamstat composition
• Secured EUR 15 million Standby Equity Purchase Agreement with Yorkville Advisors

The company expects its cash reserves to fund operations into January 2026. Management team strengthened with Julia Neugebauer joining as Chief Operating Officer from May 1, 2025. Vivoryon has discontinued investigation of varoglutamstat in Alzheimer's disease to focus resources on kidney disease development.

Vivoryon Therapeutics N.V. has secured a Standby Equity Purchase Agreement (SEPA) worth up to EUR 15 million with Yorkville Advisors Global, LP. The 36-month agreement allows Vivoryon to sell ordinary shares to Yorkville in individual tranches, with each tranche to 100% of the average daily trading volume over five days, up to 389,359 shares per tranche.

The shares will be issued at a 5% discount to market price, and the deal includes 167,028 shares as a commitment fee to Yorkville. Board members Erich Platzer and Frank Weber have agreed to lend 389,359 shares to Yorkville at no cost.

The funding will support Vivoryon's ongoing operations, preparations for a planned Phase 2b study in diabetic kidney disease for varoglutamstat, and advancement of preclinical studies for VY2149.

Vivoryon Therapeutics, a clinical stage company specializing in small molecule medicines development, has announced it will release its full year 2024 financial results and provide a corporate update on April 29, 2025.

The company will host a conference call and webcast at 3:00 pm CEST / 9:00 am EDT on the same day. The financial report will be accessible on Vivoryon's website, and participants can join the conference call through pre-registration on the provided link.

Vivoryon Therapeutics N.V. held a virtual R&D update highlighting key developments for their drug varoglutamstat. The event featured presentations from experts discussing the drug's beneficial effects on kidney function demonstrated in two independent Phase 2 studies. Key findings showed that varoglutamstat improved kidney function (eGFR) with statistical significance, with over 70% of patients responding to treatment.

The company plans to initiate a Phase 2b study in patients with type 2 diabetes and CKD stages 3b and worse. The drug's unique positioning stems from its oral availability, novel mechanism of action targeting inflammation and fibrosis through QPCTL inhibition, and demonstrated long-term safety. Notably, Vivoryon has decided to discontinue varoglutamstat's investigation in Alzheimer's disease to focus resources on kidney disease development.

Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY) has announced a virtual R&D update scheduled for February 18, 2025, at 3:00 pm CET / 9:00 am EST. The event will feature key presentations focusing on varoglutamstat's beneficial effects on kidney function and the company's clinical development plans for kidney disease treatments.

Two prominent Key Opinion Leaders (KOLs) will participate in the webcast: Dr. Tobias B. Huber, Chair of the Center of Internal Medicine at University Medical Center Hamburg-Eppendorf, serving as Medical Advisor for clinical study design, and Dr. Kevin Carroll, CEO of KJC Statistics, who will provide expertise on statistical analysis.

The session will include management presentations, discussions on varoglutamstat's market positioning, and an interactive Q&A segment for investors and analysts.